China: Patent granted to Doudna-Charpentier

In June 2017, China’s State Intellectual Property Office awarded a broad CRISPR-Cas9 patent to the Doudna-Charpentier team covering the single-guide RNA format of the CRISPR-Cas9 system and its use in any environment (including plant, animal and human cells). The Chinese patent also includes claims covering the use of CRISPR-Cas9 in producing medicines for treating disease.



Sign up to receive updates from the CRISPR Collective

Related News

US Patent Covering Optimized Guide RNA Formats for CRISPR/Cas9 in Eukaryotic Cells Issued to The Regents of the University of California, the University of Vienna, and Dr. Emmanuelle Charpentier
Emmanuelle Charpentier and Jennifer A. Doudna among the 2018 Kavli Award winners
U.S. Court of Appeals for the Federal Circuit hears oral arguments in appeal of PTAB ruling
Read moreArrow-down